(Q34585171)

3 August 2017

1 reference

title

Bivalirudin: a review of its potential place in the management of acute coronary syndromes (English)

1 reference

3 August 2017

main subject

acute coronary syndrome

1 reference

2

Greg L Plosker

1 reference

3 August 2017

author name string

Christopher I Carswell

series ordinal

1

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

62

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

841-870

1 reference

Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans

3 August 2017

cites work

1 reference

12 December 2020

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

1 reference

12 December 2020

Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile

1 reference

12 December 2020

Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.

1 reference

12 December 2020

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

12 December 2020

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

12 December 2020

The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model

1 reference

12 December 2020

Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects

1 reference

12 December 2020

Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model

1 reference

12 December 2020

In-hospital cost of percutaneous coronary revascularization. Critical determinants and implications

1 reference

12 December 2020

A comparison of reteplase with alteplase for acute myocardial infarction

1 reference

12 December 2020

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model

1 reference

12 December 2020

Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial

1 reference

12 December 2020

Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUS

1 reference

12 December 2020

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

12 December 2020

Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

12 December 2020

New anticoagulant drugs

1 reference

12 December 2020

Evaluation of the role of coronary angioplasty in patients with unstable angina pectoris

1 reference

12 December 2020

Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group

1 reference

12 December 2020

Kinetic mechanism for the interaction of Hirulog with thrombin.

1 reference

12 December 2020

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

The use of bivalirudin in patients with renal impairment.

1 reference

12 December 2020

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

1 reference

12 December 2020

Role of thrombin signalling in platelets in haemostasis and thrombosis

1 reference

12 December 2020

Bivalirudin (Angiomax) for angioplasty

1 reference

12 December 2020

Cost analysis of bivalirudin in percutaneous coronary intervention

1 reference

12 December 2020

Reactivation of unstable angina after the discontinuation of heparin

1 reference

12 December 2020

Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells

1 reference

12 December 2020

Human umbilical vein smooth muscle cells as a model to study thrombin generation and function: effect of thrombin inhibitors

1 reference

12 December 2020

Bivalirudin: a new generation antithrombotic drug

1 reference

12 December 2020

Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin

1 reference

12 December 2020

Antithrombotic therapy in patients undergoing coronary angioplasty

1 reference

12 December 2020

Thrombin functions and antithrombotic intervention

1 reference

12 December 2020

A second look at bivalirudin

1 reference

12 December 2020

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy

1 reference

12 December 2020

Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

1 reference

12 December 2020

The ideal fibrinolytic: can drug design improve clinical results?

1 reference

12 December 2020

Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction

1 reference

12 December 2020

Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty

1 reference

12 December 2020

Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin

1 reference

12 December 2020

Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up

1 reference

12 December 2020

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction

1 reference

12 December 2020

Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions

1 reference

12 December 2020

Unstable angina: current concepts of pathogenesis and treatment

1 reference

12 December 2020

Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics

1 reference

12 December 2020

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

12 December 2020

Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty

1 reference

12 December 2020

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

12 December 2020

Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.

1 reference

12 December 2020

Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury

1 reference

12 December 2020

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

12 December 2020

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

12 December 2020

Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin

1 reference

12 December 2020

Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting

1 reference

12 December 2020

Bivalirudin for percutaneous coronary interventions: development perspective.

1 reference

12 December 2020

Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery

1 reference

12 December 2020

Thrombin and antithrombotics

1 reference

12 December 2020

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

1 reference

12 December 2020

The coagulation cascade: initiation, maintenance, and regulation

1 reference

12 December 2020

A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction

1 reference

12 December 2020

The human pharmacology of thrombin inhibition.

1 reference

12 December 2020

Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials

1 reference

12 December 2020

Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease

1 reference

12 December 2020

Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention.

1 reference

12 December 2020

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

12 December 2020

Aspirin, heparin, or both to treat acute unstable angina

1 reference

12 December 2020

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

12 December 2020

A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.

1 reference

12 December 2020

Antithrombotic effects of hirulog in a rat carotid endarterectomy model

1 reference

12 December 2020

Novel Antithrombotic Drugs in Development

1 reference

12 December 2020

A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

1 reference

12 December 2020

10.2165/00003495-200262050-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1009535394

0 references

1 reference